Avalyn Pharma Inc. 8-K

What Happened

• Avalyn Pharma Inc. announced on June 17, 2026 that it has completed target enrollment in its Phase 2b MIST trial of AP01 (inhaled pirfenidone) for patients with progressive pulmonary fibrosis. The company issued a press release on the same date; that release was furnished as Exhibit 99.1 to the Form 8-K (Item 7.01, Regulation FD Disclosure). The Form 8-K was signed by CEO Lyn Baranowski.

Key Details

• Company: Avalyn Pharma Inc. (AVLN).
• Event: Completed target enrollment in the Phase 2b MIST clinical trial of AP01 (inhaled pirfenidone).
• Date filed: Form 8-K and press release dated June 17, 2026; press release furnished as Exhibit 99.1.
• Filing section: Item 7.01 (Regulation FD Disclosure); signature by CEO Lyn Baranowski.

Why It Matters

• This is a clinical development milestone: completing target enrollment means the trial has reached its planned participant number and can proceed to follow-up and eventual data analysis.
• For investors, the update reduces near-term enrollment risk for the AP01 program and signals that forthcoming trial updates (e.g., interim or topline results, timelines) may be expected next. The filing itself is a public disclosure under Regulation FD, ensuring broad market access to the news.